Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

459
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
459
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

56
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
56
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

300
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
300

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The EBV timing hypothesis: How the age of primary infection may explain global variation in multiple sclerosis.

Multiple sclerosis and related disorders·2026
Same author

The Financial Value of an Academic Neurologist.

Annals of neurology·2026
Same author

Uremic pancreatitis following routine initiation of losartan in advanced chronic kidney disease: A case report.

SAGE open medical case reports·2026
Same author

The Effect of Ocrelizumab on Anti-JC Virus Antibody Index.

Brain and behavior·2026
Same author

Rapidly Progressive and Relapsing Myelitis With Human T Lymphotropic Virus Type 1: A Case Report and Review of the Literature.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Related Experiment Video

Updated: Mar 6, 2026

Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

2.9K

Classifying PML risk with disease modifying therapies.

Joseph R Berger1

  • 1Department of Neurology, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, Gates 3W, Philadelphia, PA 19104, USA.

Multiple Sclerosis and Related Disorders
|March 12, 2017
PubMed
Summary
This summary is machine-generated.

This study categorizes the risk of progressive multifocal leukoencephalopathy (PML) with multiple sclerosis (MS) disease-modifying therapies (DMTs). Natalizumab shows the highest risk, while fingolimod and dimethyl fumarate have lesser risks, with other DMTs remaining uncertain.

Keywords:
Dimethyl fumarateDisease modifying therapyFingolimodMultiple sclerosisNatalizumabProgressive multifocal leukoencephalopathyRituximab

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.9K

Related Experiment Videos

Last Updated: Mar 6, 2026

Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

2.9K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.9K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Disease-modifying therapies (DMTs) for multiple sclerosis (MS) modulate the immune system.
  • Natalizumab is linked to a significant risk of progressive multifocal leukoencephalopathy (PML).
  • Fingolimod and dimethyl fumarate also have established PML risks in MS patients.

Purpose of the Study:

  • To systematically classify the risk of PML associated with current MS DMTs.
  • To provide a framework for understanding and contextualizing PML risk across different MS treatments.

Main Methods:

  • PML risk classification based on three criteria: predisposition by the underlying condition, drug initiation latency to PML development, and observed PML frequency.
  • Evaluation of available data on DMTs used for multiple sclerosis.

Main Results:

  • Natalizumab presents a distinct and high risk for PML.
  • Fingolimod and dimethyl fumarate are associated with significantly lower PML risks compared to natalizumab.
  • The PML risk for other MS DMTs, including rituximab, teriflunomide, and alemtuzumab, remains undetermined.

Conclusions:

  • A structured approach to stratifying DMT-associated PML risk is crucial for informed clinical decision-making and patient counseling.
  • Ongoing data collection and experience with DMTs will necessitate future revisions of PML risk assessments.